{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:11:05Z","timestamp":1770513065478,"version":"3.49.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1097\/fpc.0000000000000228","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T15:44:53Z","timestamp":1463499893000},"page":"403-413","source":"Crossref","is-referenced-by-count":6,"title":["Influence of the cytochrome P450 2D6 *10\/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder"],"prefix":"10.1097","volume":"26","author":[{"given":"Miki","family":"Nishimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikito","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Saruwatari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Ogusu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Tsuchimine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Iwashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsumasa","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Oniki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Yasui-Furukori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210213","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1527-3458.2001.tb00189.x","article-title":"Paroxetine: a review","volume":"7","author":"Bourin","year":"2001","journal-title":"CNS Drug Rev"},{"key":"R2-1-20210213","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14656566.2012.652085","article-title":"Paroxetine for the treatment of depression: a critical update","volume":"13","author":"Gibiino","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"R3-1-20210213","first-page":"CD006531","article-title":"Paroxetine versus other anti-depressive agents for depression","volume":"4","author":"Purgato","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R4-1-20210213","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/YIC.0000000000000023","article-title":"A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?","volume":"29","author":"Sanchez","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"R5-1-20210213","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1055\/s-2005-864121","article-title":"Paroxetine serum concentrations in depressed patients and response to treatment","volume":"38","author":"Gilles","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"R6-1-20210213","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1067\/mcp.2000.106128","article-title":"Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects","volume":"67","author":"Yoon","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"R7-1-20210213","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.npp.1300960","article-title":"Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder","volume":"31","author":"Findling","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R8-1-20210213","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2125.2006.02629.x","article-title":"Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling","volume":"61","author":"Feng","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R9-1-20210213","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/hup.1252","article-title":"Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders","volume":"26","author":"Yasui-Furukori","year":"2011","journal-title":"Hum Psychopharmacol"},{"key":"R10-1-20210213","first-page":"121","article-title":"Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders","volume":"7","author":"Saruwatari","year":"2014","journal-title":"Pharmgenomics Pers Med"},{"key":"R11-1-20210213","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/FTD.0000000000000036","article-title":"Therapeutic reference range for plasma concentrations of paroxetine in patients with major depressive disorders","volume":"36","author":"Tomita","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R12-1-20210213","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R13-1-20210213","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1124\/dmd.109.030551","article-title":"Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator","volume":"38","author":"Jornil","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R14-1-20210213","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1600-0447.1989.tb07176.x","article-title":"A review of the metabolism and pharmacokinetics of paroxetine in man","volume":"350","author":"Kaye","year":"1989","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R15-1-20210213","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/clpt.1992.24","article-title":"Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism","volume":"51","author":"Sindrup","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"R16-1-20210213","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.DMPK-11-RV-121","article-title":"Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance","volume":"27","author":"Teh","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"R17-1-20210213","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R18-1-20210213","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2133\/dmpk.DMPK-11-RV-111","article-title":"Population differences in major functional polymorphisms of pharmacokinetics\/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development","volume":"27","author":"Kurose","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"R19-1-20210213","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"R20-1-20210213","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00228-004-0792-6","article-title":"Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine","volume":"60","author":"Sawamura","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"R21-1-20210213","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.pnpbp.2005.11.007","article-title":"The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients","volume":"30","author":"Ueda","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R22-1-20210213","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00228-015-1855-6","article-title":"Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems","volume":"71","author":"Chen","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"R23-1-20210213","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-199937010-00003","article-title":"Population pharmacokinetics. A regulatory perspective","volume":"37","author":"Sun","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"R24-1-20210213","doi-asserted-by":"crossref","first-page":"e111066","DOI":"10.1371\/journal.pone.0111066","article-title":"Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of gamma-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis","volume":"9","author":"Ogusu","year":"2014","journal-title":"PLoS One"},{"key":"R25-1-20210213","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00008571-199508000-00005","article-title":"Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology","volume":"5","author":"Steen","year":"1995","journal-title":"Pharmacogenetics"},{"key":"R26-1-20210213","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","article-title":"The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype","volume":"83","author":"Gaedigk","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R27-1-20210213","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R28-1-20210213","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1208\/s12248-012-9320-2","article-title":"Covariate pharmacokinetic model building in oncology and its potential clinical relevance","volume":"14","author":"Joerger","year":"2012","journal-title":"AAPS J"},{"key":"R29-1-20210213","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5414\/CP201798","article-title":"Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine","volume":"51","author":"Mikami","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R31-1-20210213","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.31.3.289","article-title":"Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine","volume":"31","author":"Bertelsen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R32-1-20210213","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1124\/jpet.115.223768","article-title":"Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine","volume":"354","author":"Uttamsingh","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"R33-1-20210213","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00008571-200108000-00003","article-title":"Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates","volume":"11","author":"Ramamoorthy","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R34-1-20210213","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"R35-1-20210213","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/clpt.2010.137","article-title":"Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan","volume":"88","author":"Abduljalil","year":"2010","journal-title":"Clin Pharmacol Ther"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:23:24Z","timestamp":1620951804000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201609000-00001"}},"subtitle":["a population pharmacokinetic analysis"],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000228","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}